On Wednesday, Shares of Monsanto Company (NYSE:MON), gained 1.01% to $107.67.
Monsanto Company, declared that farmers have mapped more than 75 million row crop acres in their digital agriculture platform, up from 50 million acres in 2014. This noteworthy acre adoption represents nearly 45 percent of all corn and soybean acres planted in the U.S. The company’s digital agriculture platform comprises Climate Basic, Climate Pro and FieldView from Precision Planting. The company also declared Climate Pro, their premium web and mobile product offering, has grown considerably from its initial launch from 1 million acres last year to more than 5 million acres this year across the U.S.
Together these tools provide one account with multiple product offerings and access points. The farmer can log in on a tablet from his tractor, on a mobile phone as he scouts his fields, or on his desktop computer.
The company emphasized the importance of farmer adoption to the future success of this emerging platform. “The interest we’ve seen from farmers this year in our digital platform reinforces the impact these tools ultimately can have on our industry,” said Mike Stern, President and Chief Operating Officer for The Climate Corporation. “We want to be the digital platform of choice for farmers, and our growth this year is evidence that we’re well on that path,” said Stern.
Monsanto Company, together with its auxiliaries, provides agricultural products for farmers worldwide. It operates in two segments, Seeds and Genomics, and Agricultural Productivity.
Shares of Opko Health Inc. (NYSE:OPK), inclined 1.09% to $16.25, during its last trading session.
Opko Health, declared that the Company’s 3.0% Convertible Senior Notes due 2033 continue to be convertible by holders of such Notes through September 30, 2015. The Company has elected to satisfy its conversion obligation under the Notes in shares of the Company’s Common Stock.
This conversion right has been extended because the closing price per share of the Company’s Common Stock has exceeded $9.19, or 130% of the applicable conversion price of $7.07, for at least 20 of 30 successive trading days during the quarter ended June 30, 2015. The Company had formerly declared on April 1, 2015 that this conversion right had been triggered during the quarter ended March 31, 2015. The Notes will continue to be convertible until September 30, 2015, and may be convertible thereafter, if one or more of the conversion conditions specified in the Indenture, dated as of January 30, 2013, by and between the Company and Wells Fargo Bank N.A., is satisfied during future measurement periods. Following the Indenture, a holder who elects to convert the Notes will receive 141.4827 shares of the Company’s Common Stock plus such number of additional shares as is applicable on the conversion date per $1,000 principal amount of Notes based on the early conversion provisions in the Indenture.
Wells Fargo Bank, National Association is the trustee for the holders of the Notes and the conversion agent under the Indenture.
OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States and internationally.
Finally, Exelixis, Inc. (NASDAQ:EXEL), ended its last trade with -7.18% loss, and closed at $3.49.
Exelixis’, extended the Prescription Drug User Fee Act (PDUFA) action date for its review of Genentech’s New Drug Application (NDA) for cobimetinib by the standard extension period of three months, from August 11, 2015 to November 11, 2015.
FDA extended its review after Genentech presented, at FDA request, additional data from coBRIM, the phase 3 registrational trial of cobimetinib and vemurafenib in patients with BRAF V600 mutation-positive advanced melanoma.
Exelixis discovered cobimetinib, a selective inhibitor of MEK, internally and advanced the compound to investigational new drug (IND) status. In late 2006, Exelixis reached a partnership agreement with Genentech, under which Exelixis received initial upfront and milestone payments in connection with signing the agreement and submitting the IND. Exelixis was responsible for development of cobimetinib through the determination of the maximum tolerated dose in phase 1, at which point Genentech exercised its option to further develop the compound.
Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
